Business of the House Debate

Full Debate: Read Full Debate
Department: Leader of the House

Business of the House

Liz Twist Excerpts
Thursday 11th March 2021

(3 years, 8 months ago)

Commons Chamber
Read Full debate Read Hansard Text Read Debate Ministerial Extracts
Jacob Rees-Mogg Portrait Mr Rees-Mogg
- Hansard - - - Excerpts

The £4.8 billion levelling-up fund will spend taxpayers’ money on local infrastructure that improves everyday life across the United Kingdom, including regenerating town centres and high streets, upgrading local transport and spending money on cultural and heritage assets. The fund will operate UK-wide, extending the benefits of funding for priority local infrastructure across all regions and nations. The prospectus published at the Budget provides guidance for local areas on how to submit bids for the first round of funding for projects starting in 2021-22. That includes guidance on the process for submitting bids, the types of projects eligible for funding and how bids will be assessed. To reassure my hon. Friend, there are still 49 deals to be awarded, and the Ministry for Housing, Communities and Local Government will be making further announcements in due course, which will be the opportunity for other communities in his constituency to apply.

Liz Twist Portrait Liz Twist (Blaydon) (Lab) [V]
- Hansard - -

Two weeks ago, the National Institute for Health and Care Excellence published its provisional assessment of the drug Kuvan, for the treatment of phenylketonuria, or PKU. While it is good to see NICE recommend it be made available for children up to 18, it is hugely disappointing that it has not recommended making it available for adults. People with PKU have already waited 12 years for access to this treatment. Can we have a debate in Government time on access to medicines for rare diseases, such as Kuvan for PKU?

Jacob Rees-Mogg Portrait Mr Rees-Mogg
- Hansard - - - Excerpts

I have a great deal of sympathy with the point that the hon. Lady is making. When we represent constituents who need drugs for rare diseases, it is important that we get them. I think the principle that NICE is independent in making these decisions is also a sensible one, but it is crucial that its decisions are made in a timely way and appear to be reasonable to the country at large. NICE is a matter that will come up for debate, but it may be that the hon. Lady will want an Adjournment debate on this specific issue. I had one on Batten disease before joining the Government, and the Government proved very sympathetic to the quest for my constituent.